BAY 3178275 / Bayer - LARVOL DELTA

A patent review of GPR84 receptor antagonists (2020-present). (PubMed, Expert Opin Ther Pat) - "Recent work and patent filings reflect continued diversification of GPR84 antagonist chemotypes, but the translational outlook remains constrained by biological uncertainty and limited clinical validation. With only a small number of candidates - such as BAY‑3178275 and BGT‑004-currently in active development, further progress will require deeper mechanistic understanding and clearer definition of disease contexts in which GPR84 modulation may offer therapeutic benefit."

Journal • Review • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Neuralgia • Oncology • Pain • Ulcerative Colitis